ABDUL HAMEED: Open Payments
NPI 1750395331 · CAIRO, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$314 in 15 payments from 7 companies in 2025. Trend: 2023 $313 · 2024 $168 · 2025 $314
Food & beverage: $314
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 3 | $75 |
| Janssen Pharmaceuticals, Inc | 3 | $63 |
| ABBVIE INC. | 3 | $57 |
| Neurocrine BioSciences, Inc. | 2 | $40 |
| E.R. Squibb & Sons, L.L.C. | 2 | $32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
Products named: INVEGA SUSTENNA, VRAYLAR, VIVITROL, INGREZZA, COBENFY, ARISTADA, CAPLYTA, AUSTEDO XR.
Industry payments across NY — which companies pay providers there.
